Scientists test Two-Drug attack on Tough-to-Treat sarcomas
NCT ID NCT05180695
Summary
This study is testing the safety and early effectiveness of a new two-drug combination (HDM201 and pazopanib) for adults with advanced soft tissue sarcoma that has a specific genetic profile (p53 wild-type). The first part finds the safest dose, and the second part looks for early signs that the treatment can help control the cancer. It is for people whose cancer has grown despite at least one prior chemotherapy treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOFT TISSUE SARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Léon Bérard
Lyon, 69373, France
-
Institut Bergonié
Bordeaux, 33800, France
-
Institut Claudius Regaud
Toulouse, 31059, France
-
Institut Gustave Roussy
Villejuif, 94805, France
-
Institut Paoli-Calmettes
Marseille, 13273, France
Conditions
Explore the condition pages connected to this study.